You are here

Optimeos Life Sciences, Inc.

Company Information
174 Nassau St Ste 334
Princeton, NJ 08542-7005
United States



# of Employees: 2

Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No

Award Charts

Award Listing

  1. Highly loaded long-acting depots of therapeutic peptides

    Amount: $287,726.00

    Peptides can have exquisite potency and selectivity in treating disease, but suffer from rapid clearance. Microparticle depot formulations, where the peptide is entrapped in a water-insoluble polymer ...

    SBIRPhase I2022Department of Health and Human Services National Institutes of Health
  2. STTR Phase I: Formulation of a COVID-19 mRNA Vaccine by Inverse Flash NanoPrecipitation

    Amount: $256,000.00

    The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is the development of a novel messenger ribonucleic acid (mRNA)-based vaccine for COVID-1 ...

    STTRPhase I2021National Science Foundation
  3. Sustained Release Formulations of Therapeutic Antibodies

    Amount: $255,351.00

    This application seeks to develop a long-acting depot formulation for antibodies, using the inverse Flash NanoPrecipitation (iFNP) platform being commercialized by Optimeos Life Sciences. Microparticl ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  4. STTR Phase I: Sustained Delivery of Peptides with Inverse Flash Nanoprecipitation

    Amount: $225,000.00

    This STTR Phase I project aims to pioneer a novel approach for the sustained delivery of peptide therapeutics using nano-composite microparticles. Peptide therapeutics tend to suffer from rapid enzyma ...

    STTRPhase I2019National Science Foundation
US Flag An Official Website of the United States Government